World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
43797
World Ranking
9911
National Ranking
350

Paolo Bruzzi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Paolo Bruzzi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 452 publications — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Paolo Bruzzi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Paolo Bruzzi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Paolo Bruzzi is affiliated with Ospedale San Martino in Italy and specializes in the field of medicine, with a particular focus on oncology. Their research spans several subfields including oncology, pulmonary and respiratory medicine, cancer research, surgery, and neurology.

The scientist has contributed extensively to studies related to breast cancer treatment, cancer genomics and diagnostics, COVID-19 clinical research, sarcoma diagnosis and treatment, advanced breast cancer therapies, colorectal cancer treatments, and cancer pharmacology.

Paolo Bruzzi's notable recent publications highlight a range of clinical and therapeutic studies in these areas:

  • Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia, 2020, JAMA Internal Medicine
  • Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups, 2020, Journal of Clinical Oncology
  • Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial, 2022, Annals of Surgical Oncology
  • Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial, 2021, Cancer
  • Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial, 2021, The Lancet Oncology

Frequent coauthors collaborating with Paolo Bruzzi include:

  • Luca Boni
  • E. Barbieri
  • Giuseppe Canavese
  • Corrado Tinterri
  • Damiano Gentile

They publish regularly in several key venues, with most contributions appearing in:

  • Journal of Clinical Oncology
  • European Journal of Surgical Oncology
  • Annals of Oncology
  • Zenodo (CERN European Organization for Nuclear Research)
  • Annals of Surgical Oncology

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • ESTIMATING THE POPULATION ATTRIBUTABLE RISK FOR MULTIPLE RISK FACTORS USING CASE-CONTROL DATA

    Paolo Bruzzi;Sylvan B. Green;David P. Byar;Louise A. Brinton

  • Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.

    Paolo Spirito;Pietro Bellone;Kevin M. Harris;Paola Bernabò

  • Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy

    Barry J. Maron;Paolo Spirito;Win Kuang Shen;Tammy S. Haas

  • Adjuvant mitotane treatment for adrenocortical carcinoma.

    Massimo Terzolo;Alberto Angeli;Martin Fassnacht;Fulvia Daffara

  • Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.

    Carlo Salvarani;Giovanni Dolci;Marco Massari;Domenico Franco Merlo

  • Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)

    Andrea Bacigalupo;Teresa Lamparelli;Paolo Bruzzi;Stefano Guidi

  • Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Paolo G. Casali;Jean-Yves Blay;Alexia Bertuzzi;Stefan Bielack

  • Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

    Alessandro Gronchi;Stefano Ferrari;Vittorio Quagliuolo;Javier Martin Broto

  • HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials

    Alessandra Gennari;Maria Pia Sormani;Paolo Pronzato;Matteo Puntoni

  • Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study

    Fabio Ciceri;Chiara Bonini;Maria Teresa Lupo Stanghellini;Attilio Bondanza

  • Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

    Andrea Bacigalupo;Teresa Lamparelli;Giovanni Barisione;Paolo Bruzzi

  • Syncope and risk of sudden death in hypertrophic cardiomyopathy.

    Paolo Spirito;Camillo Autore;Claudio Rapezzi;Paola Bernabò

  • Treatment of Advanced Squamous-Cell Carcinoma of the Head and Neck with Alternating Chemotherapy and Radiotherapy

    Marco Merlano;Vito Vitale;Riccardo Rosso;Marco Benasso

  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Richard Gray;Rosie Bradley;Jeremy Braybrooke;Zulian Liu

  • MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials

    Maria Pia Sormani;Paolo Bruzzi

  • False-Positive Galactomannan Platelia Aspergillus Test Results for Patients Receiving Piperacillin-Tazobactam

    Claudio Viscoli;Marco Machetti;Paola Cappellano;Barbara Bucci

  • Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial

    Bernardo Bonanni;Matteo Puntoni;Massimiliano Cazzaniga;Giancarlo Pruneri

  • The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms

    Camillo Autore;Paola Bernabò;Caterina Stella Barillà;Paolo Bruzzi

  • Actual and preferred place of death of cancer patients. Results from the Italian survey of the dying of cancer (ISDOC)

    Monica Beccaro;Massimo Costantini;Paolo Giorgi Rossi;Guido Miccinesi

Frequent Co-Authors

Maria Pia Sormani
Maria Pia Sormani University of Genoa
Pierfranco Conte
Pierfranco Conte University of Padua
Dino Amadori
Dino Amadori University of Bologna
Claudio Viscoli
Claudio Viscoli University of Genoa
Andrea Ardizzoni
Andrea Ardizzoni University of Bologna
Domenico Palli
Domenico Palli Institute for the Study and Prevention of Cancer (Istituto per lo Studio, la Prevenzione e la Rete Oncologica)
Lisa Licitra
Lisa Licitra University of Milan
Paolo G. Casali
Paolo G. Casali University of Milan
Francesco Cognetti
Francesco Cognetti Sapienza University of Rome
Massimo Filippi
Massimo Filippi Vita-Salute San Raffaele University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in healthcare careers beyond traditional medical school? There are many accredited online programs offering alternative routes into the medical field. For those drawn to administrative and data-focused roles, medical billing and coding online schools provide convenient and affordable pathways into healthcare administration and insurance processing.

Aspiring nurses who wish to bypass certain entry exams should explore nursing school without teas test requirements. These schools allow students to focus on their coursework and clinical training instead of preparatory exams.

For those aiming for leadership, an accredited healthcare administration degree online accredited can fast-track your entry into management roles within hospitals, clinics, or insurance companies.

Registered nurses looking to advance their qualifications and practice can look into asn to fnp programs. These bridge programs offer a streamlined approach from an Associate Degree in Nursing to becoming a Family Nurse Practitioner, expanding your clinical responsibilities.

Best Scientists Citing Paolo Bruzzi

Trending Scientists

Recently Published Articles